{"id":933971,"date":"2026-02-04T08:56:40","date_gmt":"2026-02-04T13:56:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/"},"modified":"2026-02-04T08:56:40","modified_gmt":"2026-02-04T13:56:40","slug":"zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/","title":{"rendered":"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026"},"content":{"rendered":"
\n

WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management\u2019s presentation at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 1:30 p.m. ET.<\/p>\n

A live webcast and archived replay of the Company\u2019s presentation can be accessed under \u201cEvents and Presentations\u201d in the Investor & Media Relations<\/a> section of the Zenas BioPharma website<\/a>.<\/p>\n

\n About Zenas BioPharma, Inc.<\/strong>
\n
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas\u2019 lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc\u03b3RIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab\u2019s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib\u2019s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas\u2019 earlier stage programs include ZB021, a preclinical, potentially best-in-class, oral, IL-17AA\/AF inhibitor, and ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor. For more information about Zenas BioPharma, please visit https:\/\/zenasbio.com\/ and follow us on LinkedIn.<\/p>\n

The Zenas BioPharma word mark, logo mark, and the \u201clightning bolt\u201d design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.<\/p>\n

\n Investor and Media Contact:<\/strong>
\n
Argot Partners
Zenas@argotpartners.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management\u2019s presentation at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 1:30 p.m. ET. A live webcast and archived replay of the Company\u2019s presentation can be accessed under \u201cEvents and Presentations\u201d in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc. Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune … <\/p>\n

Continue reading “Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-933971","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nZenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management\u2019s presentation at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 1:30 p.m. ET. A live webcast and archived replay of the Company\u2019s presentation can be accessed under \u201cEvents and Presentations\u201d in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc. Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune … Continue reading "Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T13:56:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODA2NyM3NDA2NzEwIzIyMDc3OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026\",\"datePublished\":\"2026-02-04T13:56:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/\"},\"wordCount\":380,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODA2NyM3NDA2NzEwIzIyMDc3OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/\",\"name\":\"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODA2NyM3NDA2NzEwIzIyMDc3OTU=\",\"datePublished\":\"2026-02-04T13:56:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODA2NyM3NDA2NzEwIzIyMDc3OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODA2NyM3NDA2NzEwIzIyMDc3OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/","og_locale":"en_US","og_type":"article","og_title":"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk","og_description":"WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management\u2019s presentation at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 1:30 p.m. ET. A live webcast and archived replay of the Company\u2019s presentation can be accessed under \u201cEvents and Presentations\u201d in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc. Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune … Continue reading \"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-04T13:56:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODA2NyM3NDA2NzEwIzIyMDc3OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026","datePublished":"2026-02-04T13:56:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/"},"wordCount":380,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODA2NyM3NDA2NzEwIzIyMDc3OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/","name":"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODA2NyM3NDA2NzEwIzIyMDc3OTU=","datePublished":"2026-02-04T13:56:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODA2NyM3NDA2NzEwIzIyMDc3OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODA2NyM3NDA2NzEwIzIyMDc3OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=933971"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933971\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=933971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=933971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=933971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}